122 related articles for article (PubMed ID: 38336380)
1. N-Acetylcysteine Alters Disease Progression and Increases Janus Kinase Mutation Frequency in a Mouse Model of Precursor B-Cell Acute Lymphoblastic Leukemia.
Sams MP; Iansavitchous J; Astridge M; Rysan H; Xu LS; Rodrigues de Oliveira B; DeKoter RP
J Pharmacol Exp Ther; 2024 Mar; 389(1):40-50. PubMed ID: 38336380
[TBL] [Abstract][Full Text] [Related]
2. Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.
Lim M; Batista CR; de Oliveira BR; Creighton R; Ferguson J; Clemmer K; Knight D; Iansavitchous J; Mahmood D; Avino M; DeKoter RP
Mol Cell Biol; 2020 Aug; 40(18):. PubMed ID: 32631903
[TBL] [Abstract][Full Text] [Related]
3. Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B.
Batista CR; Lim M; Laramée AS; Abu-Sardanah F; Xu LS; Hossain R; Bell GI; Hess DA; DeKoter RP
Blood Adv; 2018 Nov; 2(21):2798-2810. PubMed ID: 30355579
[TBL] [Abstract][Full Text] [Related]
4. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
[TBL] [Abstract][Full Text] [Related]
5. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
6. Failure of tofacitinib to achieve an objective response in a
Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
[TBL] [Abstract][Full Text] [Related]
7. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
Hornakova T; Staerk J; Royer Y; Flex E; Tartaglia M; Constantinescu SN; Knoops L; Renauld JC
J Biol Chem; 2009 Mar; 284(11):6773-81. PubMed ID: 19139102
[TBL] [Abstract][Full Text] [Related]
8. JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
Uckun FM; Pitt J; Qazi S
Expert Rev Anticancer Ther; 2011 Jan; 11(1):37-48. PubMed ID: 21070101
[TBL] [Abstract][Full Text] [Related]
9. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.
Nakayama J; Yamamoto M; Hayashi K; Satoh H; Bundo K; Kubo M; Goitsuka R; Farrar MA; Kitamura D
Blood; 2009 Feb; 113(7):1483-92. PubMed ID: 19047679
[TBL] [Abstract][Full Text] [Related]
10. 1,5-Anhydroglucitol promotes pre-B acute lymphocytic leukemia progression by driving glycolysis and reactive oxygen species formation.
Zhu H; Ma H; Dong N; Wu M; Li D; Liu L; Shi Q; Ju X
BMC Cancer; 2023 Feb; 23(1):122. PubMed ID: 36747147
[TBL] [Abstract][Full Text] [Related]
11. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
[TBL] [Abstract][Full Text] [Related]
12. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia.
Blink M; Buitenkamp TD; van den Heuvel-Eibrink MM; Danen-van Oorschot AA; de Haas V; Reinhardt D; Klusmann JH; Zimmermann M; Devidas M; Carroll AJ; Basso G; Pession A; Hasle H; Pieters R; Rabin KR; Izraeli S; Zwaan CM
Leukemia; 2011 Aug; 25(8):1365-8. PubMed ID: 21537335
[No Abstract] [Full Text] [Related]
13. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.
Kameda T; Shide K; Shimoda HK; Hidaka T; Kubuki Y; Katayose K; Taniguchi Y; Sekine M; Kamiunntenn A; Maeda K; Nagata K; Matsunaga T; Shimoda K
Int J Hematol; 2010 Sep; 92(2):320-5. PubMed ID: 20697856
[TBL] [Abstract][Full Text] [Related]
14. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
Yin C; Sandoval C; Baeg GH
Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
[TBL] [Abstract][Full Text] [Related]
15. LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.
Cheng Y; Chikwava K; Wu C; Zhang H; Bhagat A; Pei D; Choi JK; Tong W
J Clin Invest; 2016 Apr; 126(4):1267-81. PubMed ID: 26974155
[TBL] [Abstract][Full Text] [Related]
16. JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.
Degryse S; Cools J
J Hematol Oncol; 2015 Jul; 8():91. PubMed ID: 26208852
[TBL] [Abstract][Full Text] [Related]
17. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression.
Yuan S; Wang X; Hou S; Guo T; Lan Y; Yang S; Zhao F; Gao J; Wang Y; Chu Y; Shi J; Cheng T; Yuan W
Leukemia; 2022 Feb; 36(2):370-382. PubMed ID: 34465864
[TBL] [Abstract][Full Text] [Related]
18. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Degryse S; Bornschein S; de Bock CE; Leroy E; Vanden Bempt M; Demeyer S; Jacobs K; Geerdens E; Gielen O; Soulier J; Harrison CJ; Constantinescu SN; Cools J
Blood; 2018 Jan; 131(4):421-425. PubMed ID: 29187379
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
Zenatti PP; Ribeiro D; Li W; Zuurbier L; Silva MC; Paganin M; Tritapoe J; Hixon JA; Silveira AB; Cardoso BA; Sarmento LM; Correia N; Toribio ML; Kobarg J; Horstmann M; Pieters R; Brandalise SR; Ferrando AA; Meijerink JP; Durum SK; Yunes JA; Barata JT
Nat Genet; 2011 Sep; 43(10):932-9. PubMed ID: 21892159
[TBL] [Abstract][Full Text] [Related]
20. N-acetyl cysteine turns EPAC activators into potent killers of acute lymphoblastic leukemia cells.
Richartz N; Pietka W; Yadav A; Bostad M; Bhagwat S; Naderi S; Naderi EH; Stokke T; Ruud E; Blomhoff HK
J Biol Chem; 2024 Jan; 300(1):105509. PubMed ID: 38042493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
